Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity

Virology

Volumn 381, Issue 2, 2008, Pages 251-260

  Pantophlet, Ralph ^a   Wrin, Terri ^b   Cavacini, Lisa A ^c,d   Robinson, James E ^e   Burton, Dennis R ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b MONOGRAM BIOSCIENCES   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cross neutralization; Epitope mapping; HIV vaccine design; V3 accessibility; V3 antibodies

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 19B; MONOCLONAL ANTIBODY 39F; MONOCLONAL ANTIBODY CO11; MONOCLONAL ANTIBODY F2A3; MONOCLONAL ANTIBODY F530; MONOCLONAL ANTIBODY LA21; MONOCLONAL ANTIBODY LE311; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; CROSS REACTION; EPITOPE MAPPING; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; SEQUENCE ANALYSIS;

ALANINE; AMINO ACID MOTIFS; AMINO ACID SEQUENCE; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; CELL LINE; CROSS REACTIONS; EPITOPES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV-1; MODELS, MOLECULAR; NEUTRALIZATION TESTS; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, TERTIARY; SEQUENCE ALIGNMENT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 54949111659     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2008.08.032     Document Type: Article

References (71)

1. Beaumont T., van Nuenen A., Broersen S., Blattner W.A., Lukashov V.V., and Schuitemaker H. Reversal of human immunodeficiency virus type 1 IIIB to a neutralization-resistant phenotype in an accidentally infected laboratory worker with a progressive clinical course. J. Virol. 75 5 (2001) 2246-2252
2. Bell C.H., Pantophlet R., Schiefner A., Cavacini L.A., Stanfield R.L., Burton D.R., and Wilson I.A. Structure of antibody F425-B4e8 in complex with a V3 peptide reveals a new binding mode for HIV-1 neutralization. J. Mol. Biol. 375 4 (2008) 969-978
3. Binley J.M., Wrin T., Korber B., Zwick M.B., Wang M., Chappey C., Stiegler G., Kunert R., Zolla-Pazner S., Katinger H., Petropoulos C.J., and Burton D.R. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78 23 (2004) 13232-13252
4. Bou-Habib D.C., Roderiquez G., Oravecz T., Berman P.W., Lusso P., and Norcross M.A. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization. J. Virol. 68 9 (1994) 6006-6013
5. Burton D.R., and Montefiori D.C. The antibody response in HIV-1 infection. AIDS 11 Suppl. A (1997) S87-S98
6. Burton D.R., Desrosiers R.C., Doms R.W., Koff W.C., Kwong P.D., Moore J.P., Nabel G.J., Sodroski J., Wilson I.A., and Wyatt R.T. HIV vaccine design and the neutralizing antibody problem. Nat. Immunol. 5 3 (2004) 233-236
7. Cao J., Sullivan N., Desjardin E., Parolin C., Robinson J., Wyatt R., and Sodroski J. Replication and neutralization of human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein. J. Virol. 71 12 (1997) 9808-9812
8. Cardoso R.M., Zwick M.B., Stanfield R.L., Kunert R., Binley J.M., Katinger H., Burton D.R., and Wilson I.A. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 22 2 (2005) 163-173
9. Chakraborty K., Durani V., Miranda E.R., Citron M., Liang X., Schleif W., Joyce J.G., and Varadarajan R. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies. Biochem. J. 399 3 (2006) 483-491
10. Chen M., Singh M.K., Balachandran R., and Gupta P. Isolation and characterization of two divergent infectious molecular clones of HIV type 1 longitudinally obtained from a seropositive patient by a progressive amplification procedure. AIDS Res. Hum. Retrovir. 13 9 (1997) 743-750
11. Cleghorn F.R., Jack N., Carr J.K., Edwards J., Mahabir B., Sill A., McDanal C.B., Connolly S.M., Goodman D., Bennetts R.Q., O'Brien T.R., Weinhold K.J., Bartholomew C., Blattner W.A., and Greenberg M.L. A distinctive clade B HIV type 1 is heterosexually transmitted in Trinidad and Tobago. Proc. Natl. Acad. Sci. U. S. A. 97 19 (2000) 10532-10537
12. Coeffier E., Excler J.L., Kieny M.P., Meignier B., Moste C., Tartaglia J., Pialoux G., Salmon-Ceron D., and Leclerc C. Restricted specificity of anti-V3 antibodies induced in humans by HIV candidate vaccines. AIDS Res. Hum. Retrovir. 13 17 (1997) 1471-1485
13. Eda Y., Murakami T., Ami Y., Nakasone T., Takizawa M., Someya K., Kaizu M., Izumi Y., Yoshino N., Matsushita S., Higuchi H., Matsui H., Shinohara K., Takeuchi H., Koyanagi Y., Yamamoto N., and Honda M. Anti-V3 humanized antibody KD-247 effectively suppresses ex vivo generation of human immunodeficiency virus type 1 and affords sterile protection of monkeys against a heterologous simian/human immunodeficiency virus infection. J. Virol. 80 11 (2006) 5563-5570
14. Frost S.D., Wrin T., Smith D.M., Kosakovsky Pond S.L., Liu Y., Paxinos E., Chappey C., Galovich J., Beauchaine J., Petropoulos C.J., Little S.J., and Richman D.D. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc. Natl. Acad. Sci. U. S. A. 102 51 (2005) 18514-18519
15. Gallo R.C. The end or the beginning of the drive to an HIV-preventive vaccine: a view from over 20 years. Lancet 366 9500 (2005) 1894-1898
16. Gao F., Yue L., Craig S., Thornton C.L., Robertson D.L., McCutchan F.E., Bradac J.A., Sharp P.M., and Hahn B.H. Genetic variation of HIV type 1 in four World Health Organization-sponsored vaccine evaluation sites: generation of functional envelope (glycoprotein 160) clones representative of sequence subtypes A, B, C, and E. WHO. Network for HIV isolation and characterization. AIDS Res. Hum. Retrovir. 10 11 (1994) 1359-1368
17. Gorny M.K., Williams C., Volsky B., Revesz K., Cohen S., Polonis V.R., Honnen W.J., Kayman S.C., Krachmarov C., Pinter A., and Zolla-Pazner S. Human monoclonal antibodies specific for conformation-sensitive epitopes of V3 neutralize human immunodeficiency virus type 1 primary isolates from various clades. J. Virol. 76 18 (2002) 9035-9045
18. Gorny M.K., Revesz K., Williams C., Volsky B., Louder M.K., Anyangwe C.A., Krachmarov C., Kayman S.C., Pinter A., Nadas A., Nyambi P.N., Mascola J.R., and Zolla-Pazner S. The V3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope. J. Virol. 78 5 (2004) 2394-2404
19. Gorny M.K., Williams C., Volsky B., Revesz K., Wang X.H., Burda S., Kimura T., Konings F.A., Nadas A., Anyangwe C.A., Nyambi P., Krachmarov C., Pinter A., and Zolla-Pazner S. Cross-clade neutralizing activity of human anti-V3 monoclonal antibodies derived from the cells of individuals infected with non-B clades of human immunodeficiency virus type 1. J. Virol. 80 14 (2006) 6865-6872
20. Gram G.J., Hemming A., Bolmstedt A., Jansson B., Olofsson S., Akerblom L., Nielsen J.O., and Hansen J.E. Identification of an N-linked glycan in the V1-loop of HIV-1 gp120 influencing neutralization by anti-V3 antibodies and soluble CD4. Arch. Virol. 139 3-4 (1994) 253-261
21. Grundner C., Mirzabekov T., Sodroski J., and Wyatt R. Solid-phase proteoliposomes containing human immunodeficiency virus envelope glycoproteins. J. Virol. 76 7 (2002) 3511-3521
22. Hartley O., Klasse P.J., Sattentau Q.J., and Moore J.P. V3: HIV's switch-hitter. AIDS Res. Hum. Retrovir. 21 2 (2005) 171-189
23. Haynes B.F., and Montefiori D.C. Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates. Expert Rev. Vaccines 5 4 (2006) 579-595
24. Haynes B.F., Ma B., Montefiori D.C., Wrin T., Petropoulos C.J., Sutherland L.L., Scearce R.M., Denton C., Xia S.M., Korber B.T., and Liao H.X. Analysis of HIV-1 subtype B third variable region peptide motifs for induction of neutralizing antibodies against HIV-1 primary isolates. Virology 345 1 (2006) 44-55
25. Hu S.L., and Stamatatos L. Prospects of HIV Env modification as an approach to HIV vaccine design. Curr. HIV Res. 5 6 (2007) 507-513
26. Hu Q.X., Barry A.P., Wang Z.X., Connolly S.M., Peiper S.C., and Greenberg M.L. Evolution of the human immunodeficiency virus type 1 envelope during infection reveals molecular corollaries of specificity for coreceptor utilization and AIDS pathogenesis. J. Virol. 74 24 (2000) 11858-11872
27. Huang C.C., Tang M., Zhang M.Y., Majeed S., Montabana E., Stanfield R.L., Dimitrov D.S., Korber B., Sodroski J., Wilson I.A., Wyatt R., and Kwong P.D. Structure of a V3-containing HIV-1 gp120 core. Science 310 5750 (2005) 1025-1028
28. Karlsson Hedestam G.B., Fouchier R.A.M., Phogat S., Burton D.R., Sodroski J., and Wyatt R.T. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat. Rev. Micro. 6 2 (2008) 143-155
29. Keele B.F., Giorgi E.E., Salazar-Gonzalez J.F., Decker J.M., Pham K.T., Salazar M.G., Sun C., Grayson T., Wang S., Li H., Wei X., Jiang C., Kirchherr J.L., Gao F., Anderson J.A., Ping L.H., Swanstrom R., Tomaras G.D., Blattner W.A., Goepfert P.A., Kilby J.M., Saag M.S., Delwart E.L., Busch M.P., Cohen M.S., Montefiori D.C., Haynes B.F., Gaschen B., Athreya G.S., Lee H.Y., Wood N., Seoighe C., Perelson A.S., Bhattacharya T., Korber B.T., Hahn B.H., and Shaw G.M. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. U. S. A. 105 21 (2008) 7552-7557
30. Keller P.M., Arnold B.A., Shaw A.R., Tolman R.L., Van Middlesworth F., Bondy S., Rusiecki V.K., Koenig S., Zolla-Pazner S., Conard P., et al. Identification of HIV vaccine candidate peptides by screening random phage epitope libraries. Virology 193 2 (1993) 709-716
31. Koch M., Pancera M., Kwong P.D., Kolchinsky P., Grundner C., Wang L., Hendrickson W.A., Sodroski J., and Wyatt R. Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. Virology 313 2 (2003) 387-400
32. Krachmarov C., Pinter A., Honnen W.J., Gorny M.K., Nyambi P.N., Zolla-Pazner S., and Kayman S.C. Antibodies that are cross-reactive for human immunodeficiency virus type 1 clade A and clade B V3 domains are common in patient sera from Cameroon, but their neutralization activity is usually restricted by epitope masking. J. Virol. 79 2 (2005) 780-790
33. Krachmarov C.P., Honnen W.J., Kayman S.C., Gorny M.K., Zolla-Pazner S., and Pinter A. Factors determining the breadth and potency of neutralization by V3-specific human monoclonal antibodies derived from subjects infected with clade A or clade B strains of human immunodeficiency virus type 1. J. Virol. 80 14 (2006) 7127-7135
34. Kramer V.G., Siddappa N.B., and Ruprecht R.M. Passive immunization as tool to identify protective HIV-1 Env epitopes. Curr. HIV Res. 5 6 (2007) 642-655
35. Larkin M.A., Blackshields G., Brown N.P., Chenna R., McGettigan P.A., McWilliam H., Valentin F., Wallace I.M., Wilm A., Lopez R., Thompson J.D., Gibson T.J., and Higgins D.G. Clustal W and Clustal X version 2.0. Bioinformatics 23 21 (2007) 2947-2948
36. Lawoko A., Johansson B., Ljunggren J., Fries A., Fredriksson R., Georgievska L., Malmvall B., Pipkorn R., Fenyo E.M., and Blomberg J. Structural prerequisites for intersubtype B and D antigenicity of the third variable envelope region (V3) of human immunodeficiency virus type 1. J. Infect. Dis. 182 1 (2000) 49-58
37. Li M., Gao F., Mascola J.R., Stamatatos L., Polonis V.R., Koutsoukos M., Voss G., Goepfert P., Gilbert P., Greene K.M., Bilska M., Kothe D.L., Salazar-Gonzalez J.F., Wei X., Decker J.M., Hahn B.H., and Montefiori D.C. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 79 16 (2005) 10108-10125
38. Liao H.X., Sutherland L.L., Xia S.M., Brock M.E., Scearce R.M., Vanleeuwen S., Alam S.M., McAdams M., Weaver E.A., Camacho Z., Ma B.J., Li Y., Decker J.M., Nabel G.J., Montefiori D.C., Hahn B.H., Korber B.T., Gao F., and Haynes B.F. A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology 353 2 (2006) 268-282
39. Montefiori D.C., Hill T.S., Vo H.T., Walker B.D., and Rosenberg E.S. Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection. J. Virol. 75 21 (2001) 10200-10207
40. Moore J.P., McCutchan F.E., Poon S.W., Mascola J., Liu J., Cao Y., and Ho D.D. Exploration of antigenic variation in gp120 from clades A through F of human immunodeficiency virus type 1 by using monoclonal antibodies. J. Virol. 68 12 (1994) 8350-8364
41. Moore J.P., Trkola A., Korber B., Boots L.J., Kessler II J.A., McCutchan F.E., Mascola J., Ho D.D., Robinson J., and Conley A.J. A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B. J. Virol. 69 1 (1995) 122-130
42. Pantophlet R., Ollmann Saphire E., Poignard P., Parren P.W., Wilson I.A., and Burton D.R. Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120. J. Virol. 77 1 (2003) 642-658
43. Pantophlet R., Wilson I.A., and Burton D.R. Improved design of an antigen with enhanced specificity for the broadly HIV-neutralizing antibody b12. Protein Eng. Des. Sel. 17 10 (2004) 749-758
44. Pantophlet R., Aguilar-Sino R.O., Wrin T., Cavacini L.A., and Burton D.R. Analysis of the neutralization breadth of the anti-V3 antibody F425-B4e8 and re-assessment of its epitope fine specificity by scanning mutagenesis. Virology 364 2 (2007) 441-453
45. Patel M.B., Hoffman N.G., and Swanstrom R. Subtype-specific conformational differences within the V3 region of subtype B and subtype C human immunodeficiency virus type 1 Env proteins. J. Virol. 82 2 (2008) 903-916
46. Phogat S., and Wyatt R. Rational modifications of HIV-1 envelope glycoproteins for immunogen design. Curr. Pharm. Des. 13 2 (2007) 213-227
47. Pinter A., Honnen W.J., He Y., Gorny M.K., Zolla-Pazner S., and Kayman S.C. The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J. Virol. 78 10 (2004) 5205-5215
48. Posner M.R., Elboim H., and Santos D. The construction and use of a human-mouse myeloma analogue suitable for the routine production of hybridomas secreting human monoclonal antibodies. Hybridoma 6 6 (1987) 611-625
49. Posner M.R., Barrach H.J., Elboim H.S., Nivens K., Santos D.J., Chichester C.O., and Lally E.V. The generation of hybridomas secreting human monoclonal antibodies reactive with type II collagen. Hybridoma 8 2 (1989) 187-197
50. Richman D.D., Wrin T., Little S.J., and Petropoulos C.J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. U. S. A. 100 7 (2003) 4144-4149
51. Rosenberg E.S., Altfeld M., Poon S.H., Phillips M.N., Wilkes B.M., Eldridge R.L., Robbins G.K., D'Aquila R.T., Goulder P.J., and Walker B.D. Immune control of HIV-1 after early treatment of acute infection. Nature 407 6803 (2000) 523-526
52. Schonning K., Jansson B., Olofsson S., Nielsen J.O., and Hansen J.S. Resistance to V3-directed neutralization caused by an N-linked oligosaccharide depends on the quaternary structure of the HIV-1 envelope oligomer. Virology 218 1 (1996) 134-140
53. Schreiber M., Wachsmuth C., Muller H., Odemuyiwa S., Schmitz H., Meyer S., Meyer B., and Schneider-Mergener J. The V3-directed immune response in natural human immunodeficiency virus type 1 infection is predominantly directed against a variable, discontinuous epitope presented by the gp120 V3 domain. J. Virol. 71 12 (1997) 9198-9205
54. Schweighardt B., Liu Y., Huang W., Chappey C., Lie Y.S., Petropoulos C.J., and Wrin T. Development of an HIV-1 reference panel of subtype B envelope clones isolated from the plasma of recently infected individuals. J. Acquir. Immune Defic. Syndr. 46 1 (2007) 1-11
55. Scott Jr. C.F., Silver S., Profy A.T., Putney S.D., Langlois A., Weinhold K., and Robinson J.E. Human monoclonal antibody that recognizes the V3 region of human immunodeficiency virus gp120 and neutralizes the human T-lymphotropic virus type IIIMN strain. Proc. Natl. Acad. Sci. U. S. A. 87 21 (1990) 8597-8601
56. Seligman S.J., Binley J.M., Gorny M.K., Burton D.R., Zolla-Pazner S., and Sokolowski K.A. Characterization by serial deletion competition ELISAs of HIV-1 V3 loop epitopes recognized by monoclonal antibodies. Mol. Immunol. 33 9 (1996) 737-745
57. Selvarajah S., Puffer B., Pantophlet R., Law M., Doms R.W., and Burton D.R. Comparing antigenicity and immunogenicity of engineered gp120. J. Virol. 79 19 (2005) 12148-12163
58. Stanfield R.L., Gorny M.K., Williams C., Zolla-Pazner S., and Wilson I.A. Structural rationale for the broad neutralization of HIV-1 by human monoclonal antibody 447-52D. Structure (Camb) 12 2 (2004) 193-204
59. Torre V.S., Marozsan A.J., Albright J.L., Collins K.R., Hartley O., Offord R.E., Quinones-Mateu M.E., and Arts E.J. Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs. J. Virol. 74 10 (2000) 4868-4876
60. Trkola A., Pomales A.B., Yuan H., Korber B., Maddon P.J., Allaway G.P., Katinger H., Barbas III C.F., Burton D.R., Ho D.D., et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J. Virol. 69 11 (1995) 6609-6617
61. Wei X., Decker J.M., Wang S., Hui H., Kappes J.C., Wu X., Salazar-Gonzalez J.F., Salazar M.G., Kilby J.M., Saag M.S., Komarova N.L., Nowak M.A., Hahn B.H., Kwong P.D., and Shaw G.M. Antibody neutralization and escape by HIV-1. Nature 422 6929 (2003) 307-312
62. White-Scharf M.E., Potts B.J., Smith L.M., Sokolowski K.A., Rusche J.R., and Silver S. Broadly neutralizing monoclonal antibodies to the V3 region of HIV-1 can be elicited by peptide immunization. Virology 192 1 (1993) 197-206
63. Wyatt R., Sullivan N., Thali M., Repke H., Ho D., Robinson J., Posner M., and Sodroski J. Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions. J. Virol. 67 8 (1993) 4557-4565
64. Wyatt R., Kwong P.D., Desjardins E., Sweet R.W., Robinson J., Hendrickson W.A., and Sodroski J.G. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393 6686 (1998) 705-711
65. Xiang S.H., Wang L., Abreu M., Huang C.C., Kwong P.D., Rosenberg E., Robinson J.E., and Sodroski J. Epitope mapping and characterization of a novel CD4-induced human monoclonal antibody capable of neutralizing primary HIV-1 strains. Virology 315 1 (2003) 124-134
66. Yang X., Lee J., Mahony E.M., Kwong P.D., Wyatt R., and Sodroski J. Highly stable trimers formed by human immunodeficiency virus type 1 envelope glycoproteins fused with the trimeric motif of T4 bacteriophage fibritin. J. Virol. 76 9 (2002) 4634-4642
67. York J., Follis K.E., Trahey M., Nyambi P.N., Zolla-Pazner S., and Nunberg J.H. Antibody binding and neutralization of primary and T-cell line-adapted isolates of human immunodeficiency virus Type 1. J. Virol. 75 6 (2001) 2741-2752
68. Zhou T., Xu L., Dey B., Hessell A.J., Van Ryk D., Xiang S.H., Yang X., Zhang M.Y., Zwick M.B., Arthos J., Burton D.R., Dimitrov D.S., Sodroski J., Wyatt R., Nabel G.J., and Kwong P.D. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445 7129 (2007) 732-737
69. Zolla-Pazner S. Identifying epitopes of HIV-1 that induce protective antibodies. Nat. Rev. Immunol. 4 3 (2004) 199-210
70. Zolla-Pazner S. Improving on nature: focusing the immune response on the V3 loop. Hum. Antib. 14 3-4 (2005) 69-72
71. Zolla-Pazner S., Zhong P., Revesz K., Volsky B., Williams C., Nyambi P., and Gorny M.K. The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1. AIDS Res. Hum. Retrovir. 20 11 (2004) 1254-1258